Skip to main content
SpringerLink
Log in

Retargeting Adenovirus for Cancer Gene Therapy

  • Chapter
  • First Online:
Gene-Based Therapies for Cancer

Part of the book series: Current Cancer Research ((CUCR))

  • 817 Accesses

Abstract

Despite the rapid progress in developing clinically relevant cancer gene therapies, successful treatment options remain elusive for many tumor types, and complete remission in patients is difficult to achieve, especially for metastatic cancers. With this in mind, viral vectors have been extensively investigated as delivery vehicles for a variety of cancer gene therapy approaches. In particular, Adenovirus (Ad)-based vectors have emerged as attractive vectors for clinical application due to their high capacity for gene transfer and their safety profile. Ad vectors have demonstrated great promise in the development of gene therapy and immunotherapy vaccines for cancer. In addition, the recent development of oncolytic Ad vectors has added significantly to the therapeutic potential of Ad-based cancer therapies. However, previous investigations with Ad vectors identified complex interactions with blood factors and nontarget cells, as well as anti-Ad immune responses, which diminish the therapeutic capacity and increase the potential for unintended side-effects. Therefore, efforts are now focused on retargeting Ad vectors to specifically bind target cells, while avoiding unfavorable native interactions. This chapter reviews the significant advances made toward retargeting Ad vectors to achieve the ultimate goal of developing a safe and effective therapy with application for a variety of cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahmed A, Thompson J, Emiliusen L et al. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat Biotechnol 2003; 21: 771–777.

    Article  PubMed  CAS  Google Scholar 

  • Akusjarvi G. Proteins with transcription regulatory properties encoded by human adenoviruses. Trends Microbiol 1993; 1: 163-170.

    Article  PubMed  CAS  Google Scholar 

  • Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007; 28: 42–58.

    Article  PubMed  CAS  Google Scholar 

  • Alemany R. Designing adenoviral vectors for tumor-specific targeting. Methods Mol Biol 2009; 542: 57–74.

    PubMed  CAS  Google Scholar 

  • Alemany R, Cascallo M. Oncolytic viruses from the perspective of the immune system. Future Microbiol 2009; 4: 527–536.

    Article  PubMed  CAS  Google Scholar 

  • Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 2009; 19: 165–178.

    Article  PubMed  CAS  Google Scholar 

  • Bachtarzi H, Stevenson M, Fisher K. Cancer gene therapy with targeted adenoviruses. Expert Opin Drug Deliv 2008; 5: 1231–1240.

    Article  PubMed  CAS  Google Scholar 

  • Baker AH, McVey JH, Waddington SN et al. The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol Ther 2007; 15: 1410–1416.

    Article  PubMed  CAS  Google Scholar 

  • Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988; 6: 616–629.

    Article  PubMed  CAS  Google Scholar 

  • Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911–5921.

    PubMed  CAS  Google Scholar 

  • Brunetti-Pierri N, Ng P. Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther 2008; 15: 553–560.

    Article  PubMed  CAS  Google Scholar 

  • Calcedo R, Vandenberghe LH, Roy S et al. Host immune responses to chronic adenovirus infections in human and nonhuman primates. J Virol 2009; 83: 2623–2631.

    Article  PubMed  CAS  Google Scholar 

  • Campos SK, Barry MA. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 2006; 349: 453–462.

    Article  PubMed  CAS  Google Scholar 

  • DiPaolo N, Ni S, Gaggar A et al. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol Ther 2006; 13: 756–765.

    Article  PubMed  CAS  Google Scholar 

  • Eruslanov E, Kaliberov S, Daurkin I et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 2009; 182: 7548–7557.

    Article  PubMed  CAS  Google Scholar 

  • Eto Y, Yoshioka Y, Mukai Y et al. Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 2008; 354: 3–8.

    Article  PubMed  CAS  Google Scholar 

  • Glasgow JN, Bauerschmitz GJ, Curiel DT, Hemminki A. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther 2004; 4: 1–14.

    Article  PubMed  CAS  Google Scholar 

  • Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006; 13: 830–844.

    Article  PubMed  CAS  Google Scholar 

  • Grable M, Hearing P. cis and trans requirements for the selective packaging of adenovirus type 5 DNA. J Virol 1992; 66: 723–731.

    PubMed  CAS  Google Scholar 

  • Greig JA, Buckley SM, Waddington SN et al. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther 2009; 17: 1683–1691.

    Article  PubMed  CAS  Google Scholar 

  • Hemminki A, Alvarez RD. Adenoviruses in oncology: a viable option? Biodrugs 2002; 16: 77–87.

    Article  PubMed  Google Scholar 

  • Hitt MM, Graham FL. Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 1990; 179: 667–678.

    Article  PubMed  CAS  Google Scholar 

  • Huang D, Pereboev AV, Korokhov N et al. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Gene Ther 2008; 15: 298–308.

    Article  PubMed  CAS  Google Scholar 

  • Jin J, Liu H, Yang C et al. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Mol Cancer Ther 2009; 8: 1387–1397.

    Article  Google Scholar 

  • Johnson L, Shen A, Boyle L et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1: 325–337.

    Article  PubMed  CAS  Google Scholar 

  • Jounaidi Y, Doloff JC, Waxman DJ. Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets 2007; 7: 285–301.

    Article  PubMed  CAS  Google Scholar 

  • Kanerva A, Zinn KR, Chaudhuri TR et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449–458.

    Article  PubMed  CAS  Google Scholar 

  • Kangasniemi L, Kiviluoto T, Kanerva A et al. Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin Cancer Res 2006; 12: 3137–3144.

    Article  PubMed  CAS  Google Scholar 

  • Kaplan JM. Adenovirus-based cancer gene therapy. Curr Gene Ther 2005; 5: 595–605.

    Article  PubMed  CAS  Google Scholar 

  • Khalighinejad N, Hariri H, Behnamfar O et al. Adenoviral gene therapy in gastric cancer: a review. World J Gastroenterol 2008; 14: 180–184.

    Article  PubMed  CAS  Google Scholar 

  • Koup RA, Lamoreaux L, Zarkowsky D et al. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol 2009; 83: 6318–6322.

    Article  PubMed  CAS  Google Scholar 

  • Lamfers M, Idema S, van Milligen F et al. Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection. Cancer Lett 2009; 274: 78–87.

    Article  PubMed  CAS  Google Scholar 

  • Li HJ, Everts M, Pereboeva L et al. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter. Cancer Res 2007; 67: 5354–5361.

    Article  PubMed  CAS  Google Scholar 

  • Li HJ, Everts M, Yamamoto M et al. Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. Cancer Res 2009; 69: 554–564.

    Article  PubMed  CAS  Google Scholar 

  • Liu Y, Koziol J, Deisseroth A, Borgstrom P. Methods for delivery of adenoviral vectors to tumor vasculature. Hum Gene Ther 2007; 18: 151–160.

    Article  PubMed  CAS  Google Scholar 

  • Liu Y, Wang H, Yumul R et al. Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment. Hum Gene Ther 2009; 20: 621–629.

    Article  PubMed  Google Scholar 

  • Mohr A, Lyons M, Deedigan L et al. Mesenchymal Stem Cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 2008; 12: 2628–2643.

    Article  PubMed  CAS  Google Scholar 

  • Mossoba ME, Medin JA. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines 2006; 5: 717–732.

    Article  PubMed  CAS  Google Scholar 

  • Nakamura K, Ito Y, Kawano Y et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004; 11: 1155–1164.

    Article  PubMed  CAS  Google Scholar 

  • Nemerow GR, Pache L, Reddy V, Stewart PL. Insights into adenovirus host cell interactions from structural studies. Virology 2009; 384: 380–388.

    Article  PubMed  CAS  Google Scholar 

  • Nettelbeck DM. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J Mol Med 2008; 86: 363–377.

    Article  PubMed  Google Scholar 

  • Ni S, Gaggar A, Di Paolo N et al. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther 2006; 13: 1072–1081.

    Article  PubMed  CAS  Google Scholar 

  • Noureddini SC, Curiel DT. Genetic targeting strategies for adenovirus. Mol Pharm 2005; 2: 341–347.

    Article  PubMed  CAS  Google Scholar 

  • Parker AL, Nicklin SA, Baker AH. Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. Curr Opin Mol Ther 2008; 10: 439–448.

    PubMed  CAS  Google Scholar 

  • Pereboev AV, Nagle JM, Shakhmatov MA et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 2004; 9: 712–720.

    Article  PubMed  CAS  Google Scholar 

  • Proudfoot O, Apostolopoulos V, Pietersz GA. Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol Pharm 2007; 4: 58–72.

    Article  PubMed  CAS  Google Scholar 

  • Rajecki M, Kanerva A, Stenman UH et al. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther 2007; 6: 742–751.

    Article  PubMed  CAS  Google Scholar 

  • Raki M, Kanerva A, Ristimaki A et al. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 2005; 12: 1198–1205.

    Article  PubMed  CAS  Google Scholar 

  • Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148–158.

    Article  PubMed  CAS  Google Scholar 

  • Rea D, Havenga MJ, van Den Assem M et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 2001; 166: 5236–5244.

    PubMed  CAS  Google Scholar 

  • Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005; 5: 411–427.

    Article  PubMed  CAS  Google Scholar 

  • Schirmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 2008; 16: 1609–1616.

    Article  PubMed  CAS  Google Scholar 

  • Segura MM, Alba R, Bosch A, Chillon M. Advances in helper-dependent adenoviral vector research. Curr Gene Ther 2008; 8: 222–235.

    Article  PubMed  CAS  Google Scholar 

  • Shi CX, Hitt M, Ng P, Graham FL. Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther 2002; 13: 211–224.

    Article  PubMed  Google Scholar 

  • Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells 2008; 25: 462–466.

    PubMed  CAS  Google Scholar 

  • Sonabend AM, Ulasov IV, Tyler MA et al. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 2008; 26: 831–841.

    Article  PubMed  CAS  Google Scholar 

  • Stoff-Khalili MA, Rivera AA, Mathis JM et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007; 105: 157–167.

    Article  PubMed  Google Scholar 

  • Stoff-Khalili MA, Rivera AA, Nedeljkovic-Kurepa A et al. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control. Breast Cancer Res Treat 2008; 108: 43–55.

    Article  PubMed  CAS  Google Scholar 

  • Tang Y, Le LP, Matthews QL et al. Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology 2008; 377: 391–400.

    Article  PubMed  CAS  Google Scholar 

  • Thacker EE, Timares L, Matthews QL. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines 2009; 8: 761–777.

    Article  PubMed  CAS  Google Scholar 

  • Tsuruta Y, Pereboeva L, Breidenbach M et al. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 2008; 14: 3582–3588.

    Article  PubMed  CAS  Google Scholar 

  • Tyler MA, Ulasov IV, Sonabend AM et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther 2009; 16: 262–278.

    Article  PubMed  CAS  Google Scholar 

  • Ulasov IV, Rivera AA, Han Y et al. Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J Neurosurg 2007; 107: 617–627.

    Article  PubMed  CAS  Google Scholar 

  • Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8: 573–587.

    Article  PubMed  CAS  Google Scholar 

  • Wang G, Li G, Liu H et al. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J Gene Med 2009; 11: 477–485.

    Article  PubMed  CAS  Google Scholar 

  • Weaver EA, Nehete PN, Buchl SS et al. Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One 2009; 4: e5059.

    Article  PubMed  Google Scholar 

  • White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 2001; 20: 7836–7846.

    Article  PubMed  CAS  Google Scholar 

  • Yang ZR, Wang HF, Zhao J et al. Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Ther 2007; 14: 599–615.

    Article  PubMed  CAS  Google Scholar 

  • Zabaleta A, Llopiz D, Arribillaga L et al. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol Ther 2008; 16: 210–217.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comprehensive Cancer Center, and Gene Therapy Center, University of Alabama at Birmingham, 901 19th Street South BMR2-508, Birmingham, AL, 35294, USA

    David T. Curiel

Authors
  1. Erin E. Thacker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David T. Curiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David T. Curiel .

Editor information

Editors and Affiliations

  1. M.D.Anderson Cancer Center, Dept. Thoracic & Cardiovascular Surgery, University of Texas, Holcombe Blvd. 1515, Houston, 77030, USA

    Jack A. Roth

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Thacker, E.E., Curiel, D.T. (2010). Retargeting Adenovirus for Cancer Gene Therapy. In: Roth, J. (eds) Gene-Based Therapies for Cancer. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6102-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-6102-0_9

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-6101-3

  • Online ISBN: 978-1-4419-6102-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation